AbbVie to present new blood cancer data at ASH 2017

AbbVie will be sharing its latest blood cancer research insights at the forthcoming American Society of Hematology (ASH) annual meeting and exposition.

Taking place in Atlanta from December 9th to 12th, the conference will see AbbVie present a total of 28 abstracts, including data from investigational studies of medicines for chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia, multiple myeloma and chronic graft-versus-host-disease.

An oral, late-breaking presentation will showcase data from the phase III MURANO study, which is evaluating venetoclax tablets in combination with rituximab in patients with relapsed/refractory CLL. This therapy was developed through a collaboration between AbbVie and Genentech.

Other therapies that will be highlighted include ibrutinib, an inhibitor of Bruton's tyrosine kinase developed by Pharmacyclics and Janssen, and the immunostimulatory antibody elotuzumab, a cell-surface glycoprotein co-developed by Bristol-Myers Squibb and AbbVie.

Dr Gary Gordon, vice-president for oncology clinical development at AbbVie, said: "Our data presentations at this year's ASH annual meeting underscore our continued commitment to patients and deep expertise in researching haematologic malignancies across various difficult-to-treat blood cancers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.